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TBC1D1 interacting proteins, 
VPS13A and VPS13C, regulate 
GLUT4 homeostasis in C2C12 
myotubes
Sharon C. Hook1, Alexandra Chadt2,3, Kate J. Heesom1, Shosei Kishida4, Hadi Al‑Hasani2,3, 
Jeremy M. Tavaré1 & Elaine C. Thomas1*
Proteins involved in the spaciotemporal regulation of GLUT4 trafficking represent potential 
therapeutic targets for the treatment of insulin resistance and type 2 diabetes. A key regulator of 
insulin‑ and exercise‑stimulated glucose uptake and GLUT4 trafficking is TBC1D1. This study aimed 
to identify proteins that regulate GLUT4 trafficking and homeostasis via TBC1D1. Using an unbiased 
quantitative proteomics approach, we identified proteins that interact with TBC1D1 in C2C12 
myotubes including VPS13A and VPS13C, the Rab binding proteins EHBP1L1 and MICAL1, and the 
calcium pump SERCA1. These proteins associate with TBC1D1 via its phosphotyrosine binding (PTB) 
domains and their interactions with TBC1D1 were unaffected by AMPK activation, distinguishing them 
from the AMPK regulated interaction between TBC1D1 and AMPKα1 complexes. Depletion of VPS13A 
or VPS13C caused a post‑transcriptional increase in cellular GLUT4 protein and enhanced cell surface 
GLUT4 levels in response to AMPK activation. The phenomenon was specific to GLUT4 because other 
recycling proteins were unaffected. Our results provide further support for a role of the TBC1D1 PTB 
domains as a scaffold for a range of Rab regulators, and also the VPS13 family of proteins which have 
been previously linked to fasting glycaemic traits and insulin resistance in genome wide association 
studies.
Skeletal muscle is a major sink for plasma glucose in the body, with insulin- and exercise-stimulated contraction 
being its principle physiological  stimuli1. These stimuli activate distinct signalling pathways, both culminating 
in the mobilisation or translocation of intracellular stores of GLUT4 glucose transporters, sequestered within 
GLUT4 storage vesicles (GSV), to the cell surface to facilitate removal of glucose from the blood. Impaired 
glucose disposal, caused by defective plasma membrane translocation of GLUT4, has been linked to insulin-
resistance and type 2  diabetes2,3. However, individuals with these diseases have preserved exercise-stimulated 
glucose uptake due to activation of insulin-independent signalling  pathways4. As such, proteins involved in 
insulin-independent glucose uptake present as attractive therapeutic targets for treatment of insulin-resistance 
and type II diabetes.
TBC1D1 is a Rab-GTPase-Activating Protein (Rab-GAP), closely related to AS160 (TBC1D4)5, that regulates 
glucose uptake in muscle  cells6. These Rab-GAP proteins maintain Rab proteins in the inactive GDP-bound form 
and hence function to prevent GLUT4 translocation in the absence of  stimuli5,7. In support of this, cells depleted 
of, or overexpressing, TBC1D1 exhibit increased and decreased plasma membrane GLUT4,  respectively5,8,9.
TBC1D1 contains multiple phosphorylation sites for the Ser/Thr kinases Akt and  AMPK5,10. Mutational 
studies have demonstrated that phosphorylation of key residues, namely  Thr596 and  Ser237 by Akt and AMPK 
respectively, are important in enabling GLUT4  translocation11,12, indicating that TBC1D1 is at a key regulatory 
position linking signalling with the trafficking steps to facilitate glucose uptake. Consequently, TBC1D1 is con-
sidered a convergence point between insulin- and contractile-stimulated  signalling13,14.
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Several lines of evidence support the importance of TBC1D1 in regulating whole body energy homeostasis. 
TBC1D1 is associated with obesity-related traits and type 2 diabetes in both  humans15–19 and  mice20–22. In addi-
tion, variation in TBC1D1 is associated with growth- and obesity-related traits in pigs, chickens and  rabbits23–27. 
Genetic knockout models of TBC1D1, in both mice and rats, have increased fatty acid oxidation, indicative of 
altered metabolic substrate  utilisation20,28,29.
Both TBC1D1 and AS160 possess two phosphotyrosine-binding (PTB) domains, a central calmodulin-bind-
ing domain and a C-terminal Rab-GAP  domain15. Whilst the function of the TBC1D1 PTB domains are poorly 
understood, evidence from  AS16030,31 and  TBC1D132–34 studies suggest regulatory and signalling roles. Indeed, 
TBC1D1 PTB domain binding of (i) the GLUT4 storage resident protein, IRAP, is disrupted by  phosphorylation35 
and (ii) AMPKα1 heterotrimeric complexes enhance phosphorylation of its key regulatory site,  Ser237 33. Conse-
quently, binding partners may represent novel effectors of TBC1D1 function, thereby influencing the subcellular 
distribution of GLUT4 and as such may serve as targets by which the pharmaceutical industry could develop a 
new generation of diabetes drugs.
Here we reveal additional proteins that bind to the PTB domains of TBC1D1, identified using Stable Isotope 
Labelling by Amino acids in Cell culture (SILAC), with this study aimed to further characterise the interactome 
and establish if these proteins play a role in regulating GLUT4 biology. Using this method, we previously identi-
fied AMPK itself as forming a stable interaction with the PTB domains of  TBC1D133. In the current study we 
show that the TBC1D1 PTB domains stably associate with several Rab regulatory proteins including MICAL1 
and EHBP1L1, the calcium pump SERCA1 and VPS13A and VPS13C. Unlike with AMPKα1-containing com-
plexes, the interaction of these novel proteins with TBC1D1 was not regulated by AMPK activation. We further 
identified VPS13A and VPS13C as regulators of stimulated GLUT4 translocation to the cell surface.
Results
TBC1D1 stably associates with proteins involved in trafficking. In our previous study we reported 
AMPKα1, as a subset of proteins, identified to interact with the TBC1D1 PTB domains through SILAC-based 
quantitative proteomics on GFP-trap based immunoprecipitations from C2C12 myotubes stably expressing a 
GFP-tagged construct consisting of the two PTB domains of TBC1D1 (GFP-PTB1 + 2; Fig. 1a)33. Here, shown 
in Fig. 1b and Supplementary Table S1, we reveal the full dataset generated in our previous study of proteins 
enriched, by 5- to 100-fold, in the GFP-PTB1 + 2 precipitates compared to the GFP control. This included known 
interactors of the TBC1D1 PTB domains; several isoforms of 14–3-3 (the α/β, γ, ε, ζ/δ and η) proteins and IRAP 
(insulin-responsive aminopeptidase)30,35–38, as we previously  reported33.
As shown in Fig. 1b, we additionally observed > 15-fold enrichment in the GFP-PTB1 + 2 precipitates of 
three members of the VPS13 family (VPS13A, VPS13C and VPS13D), three MICAL protein family members 
(MICAL1, MICAL2 and MICAL3), EHBP1L1 and Rab10. We also observed a 4.7-fold enrichment of the calcium 
pump, SERCA1.
EHBP1L1, a Rab8a effector involved in vesicle  formation39, is a paralog of EHBP1 a Rab10 effector protein 
which has been implicated in regulating GLUT4 trafficking to the plasma membrane (PM) in  adipocytes40. Both 
EHBP1L1 and MICAL proteins possess calponin-homology domains that facilitate actin binding, and coiled-
coil regions involved in protein  interactions39,41. VPS13A and VPS13C, members of the highly conserved VPS13 
 family42, are lipid binding  proteins43 that have been shown to be associated with several  organelles43–46, regulators 
of cytoskeleton  dynamics47–49 and vesicular  trafficking47,50.
The interactome was validated by western blotting a selection of proteins including VPS13A, VPS13C, 
EHBP1L1, MICAL1 and SERCA1 (Fig. 1c) which were additionally confirmed to associate with full-length GFP-
tagged TBC1D1 expressed in C2C12 myotubes (Fig. 1d) and to a FLAG-tagged TBC1D1 transgene expressed 
in mouse quadriceps muscles (Fig. 1e). These results indicate that TBC1D1 associates with a constellation of 
proteins known to facilitate trafficking, with an affinity to its PTB domains that is sufficiently high to survive 
immunoprecipitation and extensive washing. Rab10 did not appear to bind to the full-length protein with suf-
ficient affinity to survive immunoprecipitation.
Figure 1.  Identification and validation of the TBC1D1 PTB protein interactome. (a) Schematic of the 
SILAC experiment setup used to identify proteins interacting with the PTB1 and PTB2 domains (amino 
acids 1–381) of TBC1D1 in differentiated C2C12 myotubes. (b) Table of proteomics output filtered for a 
score > 30, enrichment > 4 and #PSMs > 8 (raw dataset is in Supplementary Table S1). Shown in italics are the 
previous reported  hits33. Score: the sum of the Xcorr values for the peptides matched to that protein (a high 
score generally signifies a high protein abundance and a high confidence in the detection and quantification 
by the software). Enrichment: Ratio of the quantification values of the medium (GFP-PTB1 + 2) and light 
(GFP) quantification channels. A ratio of 100 suggests that the protein was not detected at all in the light 
(GFP) channel. Coverage: percentage of the protein sequence covered by identified peptides. # PSMs (peptide 
spectrum matches): total number of identified peptide sequences (includes those redundantly identified). # 
Peptides: total number of unique identified peptides. (c) Western blot validation of proteomics results. GFP-
trap precipitates from C2C12 myotube extracts, lentivirally transduced to express either GFP or GFP-PTB1 + 2 
blotted for the proteins indicated. (d) Lysates from differentiated C2C12 myotubes lentivirally transduced 
with GFP or GFP-TBC1D1 subjected to GFP-trap and western blotting for the proteins indicated. (e) 
Homogenised quadriceps lysates from either wild type (WT) mice or mice expressing 3xFLAG-TBC1D1 were 
immunoprecipitated with an anti-FLAG antibody and resulting complexes analysed. Representative blots of 
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AICAR stimulation has no effect on the novel TBC1D1 PTB interactome. Given the regulatory 
role of TBC1D1 in AMPK-mediated glucose uptake in skeletal  muscle11,20, we next examined whether AMPK 
activation affected the association of the validated interacting proteins. Unlike our previously demonstrated 
increased association of α1-subunit containing AMPK complexes and 14-3-3 proteins with  TBC1D133, stimula-
tion with the AMPK activator AICAR did not result in any significant alteration in the association of VPS13A, 
VPS13C, MICAL1, SERCA1, EHBP1L1 or IRAP with TBC1D1 in C2C12 myotubes (Fig. 2a,b). This was despite 
enhanced AMPK and ACC phosphorylation which confirmed that AMPK was indeed activated under these 
conditions (Fig. 2c). We did, however, observe a transient increase in the interaction of calmodulin with the 
full-length TBC1D1 protein (Fig. 2a,b), presumably via the putative calmodulin-binding domain in the central 
core of  TBC1D115 since calmodulin is not observed in our PTB1 + 2 alone interactome (Fig. 1). Taken together, 
this data suggests that the novel TBC1D1 PTB-domain interactome we have validated is not subject to general 
regulation by AMPK.
Depletion of VPS13A and VPS13C increases total and stimulated surface levels of GLUT4. We 
next sought to identify if novel TBC1D1 interacting proteins have a role in regulating GLUT4 biology. We inves-
tigated the role of VPS13A and VPS13C in GLUT4 translocation to the plasma membrane, as the VPS13C 
gene locus has been linked to type 2 diabetes risk and glycaemic  traits51–59. To do this we used isoform-specific 
siRNA pools to knockdown either VPS13A or VPS13C in differentiated C2C12 myotubes stably expressing a 
GLUT4 construct possessing an exofacial HA-tag, which allowed measurement of total and cell surface exposed 
GLUT4. These siRNA pools produced a 55.4% and 58.2% reduction in VPS13A and VPS13C proteins, respec-
tively (Fig. 3a,b). Importantly, siRNA knockdown of VPS13A had no effect on protein levels of VPS13C, and 
vice versa.
We utilised the AMPK activator, AICAR, to stimulate translocation of HA-GLUT4 to the cell surface in a 
high-throughput plate-based translocation assay used to detect surface and total cellular levels of HA-GLUT4 
(Fig. 3c,d). siRNA knockdown of either VPS13A or VPS13C increased the total levels of HA-GLUT4 present in 
the cell compared to non-targeting control siRNA (Fig. 3c). This was accompanied by an enhancement in the 
proportion of cellular HA-GLUT4 at the cell surface in the presence of AICAR, but not in its absence (Fig. 3d). 
As such this resulted in VPS13A or VPS13C depleted myotubes with approximately two-fold higher level of HA-
GLUT4 present at the cell surface upon AICAR stimulation compared to control myotubes (Fig. S1). Together 
this data indicates that members of the VPS13 family of proteins are involved in regulation of subcellular dis-
tribution of GLUT4 in myotubes.
Figure 2.  AICAR stimulation has little effect on the TBC1D1 interactome. (a) Western blot analysis of GFP-
trap precipitates from differentiated C2C12 myotubes lentivirally transduced with GFP or GFP-TBC1D1, serum 
starved for 4–5 h, prior to addition of vehicle or AICAR (2 mM) for the times indicated. (b) Quantitation of data 
shown in (a). Protein pull-down was normalised to GFP-TBC1D1 precipitated and then expressed as relative 
values. as Mean ± SEM; 3–6 independent experiments; repeated measures one-way ANOVA Dunnett’s post-test 
* p < 0.05 cf Basal. (c) Total cell lysates (TCL) from (a) analysed for total and phosphorylated proteins.
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Total and surface levels of other recycling plasma membrane proteins are unaffected by 
siRNA‑mediated knockdown of VPS13A and VPS13C. We next investigated whether the effect of 
VPS13A and VPS13C depletion on total and surface levels of GLUT4 was selective for this glucose transporter, 
or impacted on a range of other membrane proteins that similarly cycle between the plasma membrane and 
cell interior. These proteins included were the insulin-regulated glucose transporter  GLUT160 and the fatty acid 
transporter  CD3661,62 as well as the constitutively recycling proteins EGFR, N-cadherin and the transferrin 
 receptor63,64.
We used a high-throughput plate-based assay to detect stably expressed HA-tagged GLUT1 and endogenous 
CD36 in C2C12 myotubes (Fig. 4a–d). In contrast to HA-GLUT4, the total cellular levels of HA-GLUT1 and 
CD36 were unaffected by siRNA knockdown of VPS13A or VPS13C (Fig. 4a,b). AICAR stimulation did not 
alter the percentage of either HA-GLUT1 (Fig. 4c) or CD36 (Fig. 4d) at the cell surface in the C2C12 myotubes, 
as anticipated, and siRNA mediated knockdown of VPS13A or VPS13C had no effect on the surface levels of 
these proteins.
The levels of expression of GLUT4, GLUT1, CD36, IRAP, EGFR, N-cadherin and the transferrin receptor 
were then examined by western blotting lysates from control, VPS13A or VPS13C depleted myotubes (Fig. 4e,f). 
Increased levels of HA-GLUT4 protein were confirmed in VPS13A or VPS13C depleted myotubes. In contrast, 
total protein levels of GLUT1, CD36, IRAP, EGFR, N-cadherin and the transferrin receptor were not significantly 
different in myotubes depleted of VPS13A or VPS13C versus the control. Taken together this data suggests 
VPS13A and VPS13C regulate GLUT4 protein levels but not that of the other recycling proteins we examined.
Figure 3.  Depletion of either VPS13A or VPS13C increases stimulated GLUT4 translocation and total GLUT4 
levels. (a) Differentiating C2C12 myoblasts were transiently transfected with non-targeting control (NTC) 
siRNA, or siRNA pool against either VPS13A or VPS13C. Endogenous protein levels were examined by western 
blotting 72 h after transfection. (b) Quantitation of data shown in (a) normalised to tubulin and then shown as 
relative values Mean ± SEM; VPS13A and VPS13C protein from 5 or 10 independent experiments respectively; 
repeated measures one-way ANOVA Tukey post-test ** p < 0.01, *** p < 0.001, **** p < 0.0001. (c) Total protein 
levels of HA-GLUT4 as measured via high-throughput plate-based translocation assay, as in (d), expressed in 
arbitrary units (AU). Mean ± SEM; 7 independent experiments; repeated measures one-way ANOVA Dunnett’s 
post-test ** p < 0.01, **** p < 0.0001 cf NTC. (d) C2C12 myotubes transiently transfected with indicated 
siRNA were serum starved for 4 h in media containing 0.2% BSA prior to addition of vehicle (black bars) or 
stimulation with AICAR (2 mM, 45 min; white bars). Surface HA-GLUT4 was measured in non-permeabilised 
cells as described in the methods. Shown is the percentage of HA-GLUT4 at the PM relative to the total level of 
HA-GLUT4. Mean ± SEM; 7 independent experiments; repeated measures two-way ANOVA Dunnett’s post-test 
** p < 0.01, *** p < 0.001 cf NTC.
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HA‑GLUT4 endocytosis, gene transcription and AMPK signalling are unaffected in myotubes 
depleted of VPS13A or VPS13C. To determine whether the effect of VPS13A and VPS13C knockdown 
was related to transcription of the GLUT4 gene, we examined HA-GLUT4 mRNA transcript levels (Fig. 5a) and 
found these to be unchanged in myotubes subjected to VPS13A or VPS13C siRNA knockdown (Fig. 5b). We 
next assessed whether the increased presentation of HA-GLUT4 at the cell surface, upon VPS13A or VPS13C 
knockdown, could be attributed to an alteration in AICAR-stimulated signalling. Stimulation of C2C12 myo-
tubes with AICAR resulted in the significant increase in phosphorylation of AMPK, in addition to the AMPK 
Figure 4.  Depletion of VPS13A and VPS13C is without effect on other cell surface proteins. C2C12 myotubes 
transiently transfected with indicated siRNA were serum starved for 4 h in media containing 0.2% BSA prior 
to stimulation with AICAR (2 mM, 45 min). Total cellular levels of (a) HA-GLUT1 or (b) CD36 expressed 
in arbitrary units (AU). Mean ± SEM; 4 independent experiments. Surface (c) HA-GLUT1 or (d) CD36 were 
measured as described in the methods. Shown is the percentage of HA-GLUT1 or CD36 at the cell surface 
relative to the total cellular level of HA-GLUT1 or CD36 respectively. Mean ± SEM; 4 independent experiments. 
(e) C2C12 myotubes transiently transfected with indicated siRNA were harvested and subjected to western 
blotting for the proteins indicated. (f) Quantitation of fluorescence-based western blot data shown in (e). Data 
were normalised to the actin loading control and expressed as a fold by comparison to the NTC condition mean 
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substrates TBC1D1 and ACC in both control and VPS13A or VPS13C depleted myotubes with no significant 
difference observed in the extent of phosphorylation upon VPS13A or VPS13C depletion (Fig. 5c,d). We then 
investigated whether the increased expression and surface levels of GLUT4 in VPS13A- or VPS13C-depleted 
GLUT4 were the result of changes in GLUT4 endocyosis using a high-throughput antibody-based GLUT4 inter-
nalisation assay after AICAR stimulation (2 mM 45 min). As shown in Fig. 5e,f, a time-dependent decrease in 
cell surface HA-GLUT4 was observed concomitant with an increase in internalised HA-GLUT4 during GLUT4 
endocytosis, but this process after 60 min was unaffected by depletion of either VPS13A or VPS13C.
Discussion
In the present study we reveal additional novel validated interacting proteins of TBC1D1, a key regulator of 
GLUT4 translocation and glucose uptake in skeletal muscle. The results add significant credibility to the concept 
that the PTB domains of TBC1D1 function as important protein–protein interaction modules. Furthermore, we 
demonstrate that members of the VPS13 family, VPS13A and VPS13C, are important in maintaining GLUT4 
homeostasis in myotubes.
We and others have previously demonstrated that the PTB domains of TBC1D1 bind to 14–3-3  proteins33,36–38, 
 IRAP30,33,35, AMPK complexes containing α1 but not α2 catalytic  subunits33 and  APPL265. Using a differentiated 
in vitro muscle cell model and intact mouse quadriceps muscle, we extend this repertoire of validated binding 
proteins to include VPS13A, VPS13C, EHBP1L1, MICAL1 and SERCA1. These proteins all interacted with the 
isolated PTB domains of TBC1D1, as well as the full-length proteins. We further demonstrate that Rab10 binds 
to the isolated PTB domains, but not to the full-length protein, at least with sufficient affinity to survive the 
immunoprecipitation procedure.
We obtained evidence for the additional presence of MICAL2, MICAL3, VPS13D, Rabggta, Thada, Epb4.1 
and Gdi2 in GFP-PTB1 + 2 immunoprecipitates. All were greater than tenfold enriched versus GFP control, how-
ever we have not formally validated these interactions using western blotting. Interestingly, we also found that 
calmodulin interacts with full-length TBC1D1 but consider this is likely to be via the central calmodulin-binding 
domain of the protein because we did not find any peptides derived from calmodulin in the GFP-PTB1 + 2 
interactome (Fig. 1a). TBC1D1 has a similar domain structure and ∼50% identical primary sequences with 
 AS1605 and it will be interesting to examine whether the proteins that bind TBC1D1 also interact with AS160.
In contrast to our previous observations with 14-3-3 and  AMPK33, and a recent report with  IRAP35, pharma-
cological activation of AMPK in C2C12 myotubes did not significantly affect the interaction of TBC1D1 with 
VPS13A, VPS13C, EHBP1L1, SERCA1, MICAL1 or IRAP (Fig. 2). The AMPK phosphorylation site at  Ser237 
within PTB2 provides part of the basis by which AMPKα1 containing complexes bind to TBC1D1. Intriguingly, a 
recent study showed IRAP binding TBC1D1 was disrupted upon phosphorylation of TBC1D1 by AMPK or Akt 
in an in vitro  system35 which may suggest stoichiometry of phosphorylation and/or cellular context, including 
other interacting proteins, play a role in regulating this interaction. Future studies will be required to establish if 
other stimuli of GLUT4 translocation modulate the TBC1D1 interactome, particularly insulin to which C2C12 
cells are poorly responsive, and muscle contraction in intact muscles.
In further exploring the role of TBC1D1 interactors, we focussed specifically on both VPS13C, because poly-
morphisms near its gene locus have previously been associated with type 2 diabetes risk and glycaemic  traits51–59, 
and VPS13A, as it is the closest VPS13C paralogue of the VPS13  proteins42. Moreover, while VPS13D was also 
identified as an interactor (Fig. 1b) we were unable to validate it via western blotting with the limited commercial 
antibodies available. VPS13 proteins have been reported to bind to a PxP motif on adaptor proteins in endosomes, 
vacuole membranes and mitochondria of  yeast66,67. Whether this sequence-dependent recruitment is important 
in the binding of mammalian VPS13 proteins to adaptor proteins remains to be established, however, interest-
ingly, both PTB1 and PTB2 domains of TBC1D1 possess PxP motifs in surface exposed regions of our homology 
 models68. These may serve to recruit VPS13 proteins to membrane compartments such as GSVs, via TBC1D1.
Using siRNA-mediated knockdown in C2C12 myotubes, we found that depletion of either VPS13A or 
VPS13C resulted in increased levels of GLUT4 protein (Figs. 3d and 4f), but not of the mRNA transcript (Fig. 5a). 
This suggests that the effect occurs post-transcriptionally. The phenomenon appears to be specific for GLUT4 
as other proteins that cycle between the cell surface and intracellular locations and engage a range of trafficking 
and sorting machineries (GLUT1, IRAP, transferrin receptors, CD36, EGFR and N-cadherin) were unaffected, 
as determined by (i) high-throughput plate-based assay on intact myotubes (Fig. 4c,d) and (ii) western blotting 
of myotube lysates (Fig. 4e,f). A lack of effect on IRAP expression and trafficking is, therefore, surprising given 
that it shares much of the same trafficking itinerary and machinery as GLUT4. While this manuscript was in 
preparation, a study by Munoz-Braceras et al.69 reported in HeLa cells VPS13A interacts with the lysosomal 
protein Rab7A and VPS13A depletion diminished lysosomal degradation. Among several cargo investigated 
EGFR degradation was reduced, which contrasts with our results; it is currently unclear how VPS13A may play 
a role in lysosomal function. AICAR stimulated signalling, including phosphorylation of  Ser237 on TBC1D1, 
remained intact in myotubes depleted of VPS13A or VPS13C (Fig. 5c,d). Moreover, the increased presence of 
GLUT4 at the cell surface upon AICAR stimulation was not due to reduced GLUT4 endocytosis as the rate of 
internalisation from the surface was indistinguishable between control and VPS13A or VPS13C depleted myo-
tubes (Fig. 5e,f). Together this suggests the elevated cell surface GLUT4 levels results from an altered exocytosis 
profile. Future studies will need to investigate the kinetics of GLUT4 exocytosis in addition to establishing if 
there is increased sequestered GLUT4 in GSVs available for translocation upon AICAR stimulation in VPS13A 
and VPS13C depleted cells.
In contrast to our observations with VPS13A and VPS13C depletion, the expression of the GLUT4 pro-
tein is known to be reduced in skeletal muscles of mouse models of TBC1D1  deficiency20–22,70 a phenomenon 
which has been attributed to missorting and enhanced post-translational degradation of the  protein71. Future 
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investigations will be required to determine the dependence of the interaction of TBC1D1 with VPS13A and 
VPS13C in regulating stimulated GLUT4 translocation and expression levels as well as confirming the distinct 
step(s) in the pathway modulated by VPS13A/C depletion.
The precise biological functions of VPS13A and VPS13C are currently unclear as they have been ascribed to be 
involved in several biological pathways. Recent evidence has shown VPS13A and VPS13C transport glycerolipids, 
such as phosphatidylcholine and phosphatidylinositol, between membrane compartments via a hydrophobic 
tunnel and hence act as a tether between the ER and LE/Lysosome (VPS13C), mitochondria (VPS13A) and 
lipid droplets (VPS13A/C)43. As lipid transporters, VPS13A and VPS13C have the capacity to control the lipid 
homeostasis of different  membranes43 and hence the capacity to alter the composition of different compartments. 
Little is known about the lipid profile of the specialised GLUT4 compartment, although it is known that changes 
in plasma membrane lipids, evoked in response to insulin, promote GSV fusion with the plasma  membrane72. 
An intriguing possibility is that through modulating the lipid profile of the GSV, the VPS13 proteins could alter 
the fusion competency of the GSV. Given VPS13A or VPS13C depletion enhances AICAR-stimulated GLUT4 
translocation, it could suggest maintenance of GSV lipid composition by these proteins acts to limit fusion 
competency.
The function of TBC1D1 has been best characterised in the context of skeletal muscle, however emerging 
evidence supports a role for TBC1D1 in other tissues including the  pancreas73–75. On the basis that ablation of 
TBC1D1 results in a mild insulin secretion  phenotype74,76 and genome wide association studies have linked the 
VPS13C locus to beta cell  impairment51,56,57,77,78, a role for the VPS13 proteins and other TBC1D1 interactors in 
the insulin secreting beta cell should be explored.
Intriguingly, several of the other proteins we found in the TBC1D1 PTB1 + 2 precipitates are regulators of 
Rab proteins. This includes MICAL1 which binds  Rab1079 and EHBP1L1 which binds  Rab839, both of which we 
validated as interactors by western blotting (Fig. 1). Two other proteins were identified in the TBC1D1 interac-
tome, Rabggta and Gdi2. While we did not formally validate these by western blotting, they were 100- and 13-fold 
enriched in the PTB1 + 2 precipitates versus controls (Fig. 1b). Rabggta is a geranylgeranyl transferase type-2 that 
adds hydrophobic geranylgeranyl moieties to the C-terminus of many of the Rab proteins and is critical for their 
delivery to the correct intracellular target membrane  compartments80. Gdi2 is a Rab GDP-dissociation inhibitor 
that binds geranylgeranylated Rab  proteins81 and is required for the delivery and removal of Rab proteins from 
their target  membranes82.
Rab2A, 8A, 8B, 10, 14, 28, 32, 33B and 34 are known substrates for the GTPase Activating Protein (GAP) 
domain located at the C-terminus of  TBC1D15,7,83. The association of an array of Rab regulatory proteins with 
the N-terminal PTB domains of TBC1D1 could provide a mechanism for carefully orchestrating the binding 
and activity of an array of cognate Rab proteins bound to the C-terminal GAP domain at different stages of the 
GLUT4 trafficking cycle through the cell. The interaction of TBC1D1 with the calcium pump SERCA1 is also 
intriguing and will require further investigation, most especially given the fact that muscle contraction is an 
important physiological regulator of muscle glucose uptake.
In summary, our results provide increasingly convincing proof that the PTB domains of TBC1D1 serve 
as a scaffold that is capable of recruiting a constellation of proteins and regulators involved in GLUT4 vesicle 
trafficking. Understanding the precise nature of these protein interactions represents an important next step in 
validating whether these have the potential to serve as therapeutic targets for the treatment of insulin-resistance 
and type 2 diabetes.
Materials and methods
Antibodies and reagents. Unless otherwise stated all reagents were from Sigma-Aldrich. Primary 
antibodies against pan-AMPK-α (#2532), pAMPK  Thr172 (#2531), ACC (#3876), pACC  Ser79 (#3661), EGFR 
(#2232), IRAP (#3808), N-cadherin (#14215), Rab10 (#8127S) and rabbit FLAG (#2368) were from Cell Signal-
ing Technology. CD36 (ab124515), Calmodulin (ab45689), GLUT1 (ab115730) and SERCA1 (ab129104) were 
from Abcam. From Santa Cruz Biotechnology Inc were antibodies against pan-14-3-3 (sc-629) and transfer-
Figure 5.  HA-GLUT4 endocytosis, gene transcription and AICAR-stimulated signalling are unaffected in 
myotubes depleted of VPS13A or VPS13C. Differentiating C2C12 myoblasts were transiently transfected 
with non-targeting control (NTC) siRNA or siRNA pool against either VPS13A or VPS13C. (a) RNA was 
extracted 72 h post transfection and relative mRNA transcript levels of HA-GLUT4 as determined by qRT-
PCR. (b) Confirmation of siRNA mediated knock-down of VPS13A and VPS13C via qRT-PCR. Mean ± SEM; 
3 independent experiments; Welch’s t-test * p < 0.05. (c) Protein levels were examined by western blotting 
72 h after transfection following serum starvation for 4 h in media containing 0.2% BSA prior to addition of 
vehicle (black bars) or AICAR (2 mM, 45 min; white bars). (d) Quantitation of fluorescence-based western 
blot data shown in (c). AMPK phosphorylation normalised to total AMPKα expression; ACC phosphorylation 
normalised to total ACC expression; TBC1D1 phosphorylation normalised to total TBC1D1 expression. 
All displayed as a fold over mean NTC basal phosphorylation. Mean ± SEM; 4 independent experiments; no 
significant difference cf NTC basal or cf NTC AICAR two-way ANOVA Dunnett’s post-test. (e,f) Differentiating 
C2C12 myoblasts were transiently transfected with non-targeting control (NTC) siRNA (blue circles), or siRNA 
pool against either VPS13A (red squares) or VPS13C (green triangles). Myotubes were then serum starved for 
4 h in media containing 0.2% BSA prior to AICAR addition (2 mM, 45 min), subsequent labelling with anti-HA 
antibody and processing as described in the materials and methods. (e) Detected bound antibody to HA-GLUT4 
at the cell surface over time. (f) Detected internalised antibody bound to HA-GLUT4 over time. Mean ± SEM; 4 
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rin receptor (sc-65882). Other antibodies were EHBP1L1 (#PAB15793; Abnova), GFP (118144600001; Roche), 
HA.11 16B12 (901503; Biolegend), MICAL1 (14818–1-AP; proteintech), pTBC1D1  Ser237 (#07-2268; Merck-
Millipore), VPS13C (HPA043356; Atlas Antibody), β actin (A1978), Tubulin (T9026) and mouse FLAG (F1804). 
VPS13A antibody was produced as previously  described84. Secondary antibodies used were conjugated with an 
AlexaFluor (Invitrogen) or HRP (Cell Signaling Technology or Jackson ImmunoResearch). AICAR was from 
Tocris.
Mouse model. Transgenic MCK-3xFLAG-Tbc1d1 mice with muscle-specific overexpression of Tbc1d1 
were generated as previously  described33 and kept in accordance with the National Institutes of Health guide-
lines for the care and use of laboratory animals, and all experiments were approved by the Ethics Committee 
of the State Ministry of Agriculture, Nutrition and Forestry (State of North Rhine-Westphalia, Germany). Male 
mice between 10 and 14 weeks were sacrificed by cervical dislocation, quadricep muscle dissected and directly 
snap-frozen in liquid nitrogen.
Molecular biology. Constructs for lentiviral expression of full-length TBC1D1 and TBC1D1 PTB1 + 2, 
amino acids 1–381 based on secondary structure  prediction68, were cloned as previously  described33 into pXLG3. 
Also cloned into pXLG3 were HA-GLUT4 and HA-GLUT1, both with a HA-tag in the first exofacial loop, from 
pQB125-HA-GLUT485 and pCDNA3-HA-GLUT186 respectively.
Cell culture. C2C12 (American Type Culture Collection) were cultured in DMEM supplemented with 10% 
(v/v) FBS (Invitrogen), 50 IU/ml penicillin, 50 μg/ml streptomycin and 2 mM glutamine. C2C12 myoblasts were 
differentiated into myotubes as previously  described87. HEK293T cells were used to produce lentiviral particles 
which were subsequently added to C2C12 myoblasts to generate stably transduced cell lines. Transduction effi-
ciency was 80–85% as determined by immunofluorescence.
SILAC interactome analysis. SILAC samples were generated in our previous  study33, which described 
only a subset of the interacting proteins, with this current study we reveal the full dataset. Briefly, transduced 
C2C12 myoblasts were expanded in R0K0 or R6K4 isotopically labelled DMEM (Dundee Cell Products) sup-
plemented with 10% (v/v) dialysed FBS (Dundee Cell Products) for at least six passages prior to differentiation 
to achieve full labeling. Myoblasts were then differentiated in R0K0 or R6K4 isotopically labelled DMEM supple-
mented with 2% (v/v) dialysed horse serum. Myotubes were harvested in precipitation buffer 50 mM Tris–HCl 
pH 7.4, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 0.5% NP40, 1 mM DTT, 50 mM NaF, 5 mM 
 Na4P2O7, 1 mM  Na3VO4, 0.5 mM PMSF, Calbiochem protease inhibitor cocktail), lysates incubated (4 °C, 1 h) 
with GFP-trap beads (ChromoTek), precipitates washed four times with precipitation buffer and samples pooled 
prior to eluting, separation on NuPAGE 4–12% precast gel (Invitrogen) and Nano LC–MS/MS on an Orbitrap 
Velos mass spectrometer (Thermo Fisher Scientific). Mass spectrometric detection and quantification was per-
formed as previously  published88.
Immunoprecipitation and western blot analysis. Transduced C2C12 myotubes were harvested in 
precipitation buffer and GFP-trap performed as per above. For mouse muscle immunoprecipitations, protein-G-
coated agarose beads pre-conjugated with anti-FLAG antibody were blocked in precipitation buffer containing 
1% (w/v) BSA prior to incubation overnight at 4 °C with homogenised quadriceps muscle (4 mg) or precipita-
tion buffer and subsequent washing, as previously  described33. For analysis of total cell lysates, myotubes were 
harvested in ice-cold lysis buffer (50  mM HEPES pH 7.4, 150  mM NaCl, 1% Triton-X-100, 1  mM  Na3VO4, 
30 mM NaF, 10 mM  Na4P2O7, 10 mM EDTA, 0.5 mM PMSF, Calbiochem protease inhibitor cocktail), protein 
content determined by BCA assay (Thermo Fisher Scientific) and equal amounts resolved by SDS-PAGE. Stand-
ard western blot procedures were performed. Fluorescently labelled secondary antibodies were detected via a 
LI-COR Odyssey infrared imaging system and HRP-conjugated secondary antibodies via ECL. Samples were 
normalized to loading control, total protein or to precipitated protein as indicated in the legends. Subsequently 
western blot values were normalised to the sum of all data points in a replicate (normalisation by summation)89 
(Figs. 2b, 3b) or normalised to the mean of the control (Figs. 4f, 5d).
siRNA knockdown. For siRNA knockdown, after 48  h in differentiation media differentiating C2C12 
cells were transfected with siRNA using DharmaFECT (Dharmacon) according to manufacturer’s instructions 
replacing back to differentiation media after 4 h. The siRNA from GE Healthcare used in this study were: ON-
TARGETplus non-targeting pool (D-001810-10), ON-TARGETplus mouse VPS13A (M-066653-00) and ON-
TARGETplus mouse VPS13C (L-053177-00). Myotubes were assayed 72 h after transfection.
GLUT4 translocation and antibody uptake assays. For the GLUT translocation assays, C2C12 myo-
blasts or transduced C2C12 myoblasts expressing either HA-GLUT4 or HA-GLUT1 were plated in triplicate at 
7000 cells per well of a 96 well plate coated with 1% gelatin and differentiated as per above. 68 h after siRNA 
transfection myotubes were serum starved for 4 h in media containing 0.2% (w/v) BSA with vehicle or AICAR 
(2  mM) added for times indicated, fixed in 4% (v/v) paraformaldehyde (Electron Microscope Services) and 
quenched with 0.15 M glycine. To detect surface levels of HA-GLUT4 or HA-GLUT1, cells were firstly incubated 
with blocking solution (1% (w/v) BSA/3% (v/v) goat serum/PBS) and then with anti-HA antibody (1:500) in 1% 
(w/v) BSA/PBS. To detect total cellular levels of HA-GLUT4 or HA-GLUT1 cells were incubated with blocking 
solution containing 0.2% (w/v) saponin and antibody solution containing 0.2% (w/v) saponin. All cells were 
11
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then washed thrice in PBS, incubated in blocking solution and then in anti-mouse secondary antibody coupled 
to AlexaFluor700 (1:200) in 1% (w/v) BSA/PBS and finally washed thrice in PBS. Signal was detected by a LI-
COR Odyssey infrared imaging system in plate mode. To account for any non-specific antibody labelling, the 
signal detected in cells not expressing HA-GLUT4 protein was subtracted. CD36 translocation assays were per-
formed the same except using antibodies to detect CD36 (1:500) and an anti-rabbit secondary antibody coupled 
to AlexaFluor800.
For the antibody uptake assays, cells were plated, differentiated, transfected and allowed to basal as per the 
translocation assay, prior to stimulation with AICAR (2 mM 45 min). To label cell surface HA-GLUT4, cells 
were firstly washed thrice in ice-cold DMEM, then incubated on ice with anti-HA antibody (1:200) in DMEM 
for 30 min and washed thrice in ice-cold DMEM to remove unbound antibody. Cells were either immediately 
fixed with 4% (v/v) paraformaldehyde at 37 °C or returned to 37 °C/5%  CO2 for 30 or 60 min to allow uptake of 
the antibody to occur prior to fixation. To label antibody bound at the cell surface, washed cells were incubated 
in blocking solution then with anti-mouse secondary antibody coupled to AlexaFluor700 (1:500) in 1% (w/v) 
BSA/PBS. After washing, control wells or wells to detect internalised antibody were incubated with blocking 
solution with or without 0.2% (w/v) saponin respectively, followed by incubation with anti-mouse secondary 
antibody coupled to AlexaFluor800 (1:500) in 1% (w/v) BSA/PBS with or without 0.2% (w/v) saponin respec-
tively. Following washing, all wells were incubated with blocking solution containing 0.2% (w/v) saponin, washed 
and fluorescence at 700 nm and 800 nm was detected using a LI-COR Odyssey infrared imaging system in plate 
mode. To account for any non-specific background surface labelling, the signal detected on cells not expressing 
HA-GLUT4 protein was subtracted. To account for any non-specific background surface labelling when detect-
ing internalized antibody, the signal detected from non-permeabilised wells, at the equivalent timepoint, was 
also subtracted.
qRT‑PCR. RNeasy kit (Qiagen) was used to extract total RNA from C2C12 myotubes. qRT-PCR was per-
formed using the SuperScript III Platinum SYBR Green One-Step qRT-PCR kit (Invitrogen). All samples were 
normalised to levels of GAPDH mRNA. Primers used for amplification of fragments are listed in Table S2.
Statistics. Statistical analyses were performed using GraphPad Prism 8.4.3 software. To account for variabil-
ity between experiments repeated measures ANOVA was used to “block” treatment data with the control data 
as  appropriate90. As indicated in the figure legends, for comparisons of two groups Welch’s t-test was used; for 
multiple comparisons the following statistical tests were used: repeated measures one-way ANOVA followed by 
Dunnett’s post-test or Tukey post-test, or two-way ANOVA followed by Tukey post-test or Dunnett’s post-test.
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